BioCentury | Dec 8, 2008
Company News

U.S. Bioscience other research news

...term with two two-year extension options, and could mean $2 million in revenues to UBS. U.S. Bioscience Inc....
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...MEDI was the acquirer, making its first big purchase in September 1999 when it bought U.S. Bioscience Inc....
...and investors didn't mind that the company was giving away a 7% ownership stake to U.S. Bioscience...
...its biggest deal - the purchase of Aviron for $1.5 billion in stock. While the U.S. Bioscience...
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...sanofi-aventis) 1 (464) (B) Ethyol amifostine Reduce platinum toxicity in non-small cell lung cancer 3/15/96 U.S. Bioscience...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BioCentury | Dec 15, 2003
Strategy

The case for small partners

...Robert Capizzi, vice president of medical affairs at Novacea, was head of clinical research at U.S. Bioscience Inc....
BioCentury | Aug 11, 2003
Regulation

A little less ODAC

...recommending approval of Ethyol in December 1994. Six months later, using exactly the same data, U.S. Bioscience Inc....
...such as cyclophosphamide, as well as platinum agents such as cisplatin. At the second panel, U.S. Bioscience...
BioCentury | Aug 4, 2003
Strategy

MedImmune's appetite for truffles

...MedImmune Inc. 's biggest deals - the acquisitions of U.S. Bioscience Inc. and Aviron - were been geared...
BioCentury | Mar 10, 2003
Clinical News

Ethyol thiophosphate cytoprotective agent regulatory update

...the product last year. The company acquired Ethyol through its $492 million stock acquisition of U.S. Bioscience...
BioCentury | Mar 5, 2003
Company News

MedImmune discloses Ethyol issues

...of the product last year. It acquired Ethyol through its $492 million stock acquisition of U.S. Bioscience...
BioCentury | Sep 3, 2002
Strategy

Back to School 2002: The sweet spot

...II trials in leiomyosarcoma at the time (see BioCentury, March 1, 1999). Next, MEDI acquired U.S. Bioscience Inc....
Items per page:
1 - 10 of 138
BioCentury | Dec 8, 2008
Company News

U.S. Bioscience other research news

...term with two two-year extension options, and could mean $2 million in revenues to UBS. U.S. Bioscience Inc....
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...MEDI was the acquirer, making its first big purchase in September 1999 when it bought U.S. Bioscience Inc....
...and investors didn't mind that the company was giving away a 7% ownership stake to U.S. Bioscience...
...its biggest deal - the purchase of Aviron for $1.5 billion in stock. While the U.S. Bioscience...
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...sanofi-aventis) 1 (464) (B) Ethyol amifostine Reduce platinum toxicity in non-small cell lung cancer 3/15/96 U.S. Bioscience...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BioCentury | Dec 15, 2003
Strategy

The case for small partners

...Robert Capizzi, vice president of medical affairs at Novacea, was head of clinical research at U.S. Bioscience Inc....
BioCentury | Aug 11, 2003
Regulation

A little less ODAC

...recommending approval of Ethyol in December 1994. Six months later, using exactly the same data, U.S. Bioscience Inc....
...such as cyclophosphamide, as well as platinum agents such as cisplatin. At the second panel, U.S. Bioscience...
BioCentury | Aug 4, 2003
Strategy

MedImmune's appetite for truffles

...MedImmune Inc. 's biggest deals - the acquisitions of U.S. Bioscience Inc. and Aviron - were been geared...
BioCentury | Mar 10, 2003
Clinical News

Ethyol thiophosphate cytoprotective agent regulatory update

...the product last year. The company acquired Ethyol through its $492 million stock acquisition of U.S. Bioscience...
BioCentury | Mar 5, 2003
Company News

MedImmune discloses Ethyol issues

...of the product last year. It acquired Ethyol through its $492 million stock acquisition of U.S. Bioscience...
BioCentury | Sep 3, 2002
Strategy

Back to School 2002: The sweet spot

...II trials in leiomyosarcoma at the time (see BioCentury, March 1, 1999). Next, MEDI acquired U.S. Bioscience Inc....
Items per page:
1 - 10 of 138